Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP)

Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 57,675 K
  • Annual Income, $ -45,997 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (N/A)
  • Most Recent Dividend N/A on N/A
  • Sector N/A
  • INDUSTRY GROUPING N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.58 +39.73%
on 11/25/25
9.68 -4.96%
on 12/16/25
+2.50 (+37.31%)
since 11/24/25
3-Month
6.27 +46.73%
on 11/14/25
9.68 -4.96%
on 12/16/25
+0.12 (+1.32%)
since 09/24/25
52-Week
4.72 +94.92%
on 04/15/25
9.85 -6.55%
on 09/02/25
+2.60 (+39.39%)
since 12/24/24

Most Recent Stories

More News
Fortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission

MIAMI, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the...

FBIO : 3.67 (+1.94%)
FBIOP : 9.20 (-0.54%)
Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights 

Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received...

FBIO : 3.67 (+1.94%)
FBIOP : 9.20 (-0.54%)
Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics’ Global Phase 3 Trials of Dotinurad for the Treatment of Gout

MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys...

FBIO : 3.67 (+1.94%)
FBIOP : 9.20 (-0.54%)
Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics’ $205 Million Series A Financing

Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange...

FBIO : 3.67 (+1.94%)
FBIOP : 9.20 (-0.54%)
Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, Inc. (“Cyprium”), today announced that the...

FBIO : 3.67 (+1.94%)
FBIOP : 9.20 (-0.54%)
Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

MIAMI, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term...

FBIO : 3.67 (+1.94%)
FBIOP : 9.20 (-0.54%)
Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received ~$28 million at closing and is eligible to receive up to an additional $4.8 million under a contingent value right...

FBIO : 3.67 (+1.94%)
FBIOP : 9.20 (-0.54%)
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIO : 3.67 (+1.94%)
FBIOP : 9.20 (-0.54%)
Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO : 3.67 (+1.94%)
DERM : 8.13 (+2.14%)
CKPT : 4.26 (+0.71%)
FBIOP : 9.20 (-0.54%)
Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIO : 3.67 (+1.94%)
FBIOP : 9.20 (-0.54%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar